Global Post-Hemorrhagic Anemia Treatment Market Definition
Post-hemorrhagic anemia is a condition that occurs when a person loses a massive amount of blood so quickly that it leads to deficiency. On the other hand anemia is a condition in which the count of red blood cells drastically decreases and further production is slowed down. It leads to low secretion of hemoglobin, which affects the RBCs production as hemoglobin is the protein that aids the oxygen flow through the red blood cells.
Post hemorrhage anemia have various symptoms that can common people to understand its severity. These symptoms include feeling of tiredness, dizziness and lightheaded, irregular or rapid heartbeat, lack of breath and urination. It also causes pale skin, loss of appetite and trouble in concentrating. The intensity of these symptoms depends on the amount of the blood loss. Other than this, the occurrence of post hemorrhage anemia can medically be diagnosed by blood test that includes the reading of red blood cells, white blood cells, and platelets. Other methods for diagnosis are bowel movement and urine samples and endoscopy for checking any internal bleeding.
To manage the post-hemorrhage anemia, proper rest is very important followed by eating food that is rich in vitamin C and iron. It can be medically treated by blood transfusion, to replenish the lost blood, and by surgery to stop the blood loss by fixing the injury. The risk of post hemorrhage is increased by ulcers, blood disorders, people who consume blood thinning medicines, heavy menstruation, and genetic blood diseases.
Global Post-Hemorrhagic Anemia Treatment Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 5 Billion |
|
Forecast Year Market Size (2035) |
~ USD 12 Billion |
|
Regional Scope |
|
Global Post-Hemorrhagic Anemia Treatment Market Size, Forecast, and Trend Highlights Over 2023 - 2035
The global post-hemorrhagic anemia treatment market is estimated to garner a revenue of around USD 12 Billion by the end of 2035 by growing at a CAGR of ~6% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of nearly USD 5 Billion in the year 2022. The growth of the market can be attributed to the higher cases of road accidents and trauma. Sudden accidents can cause severe injuries that leads to heavy blood loss. Around the world, 1.35 million people die due to road accident every year. Nearly 3,700 people per day die worldwide in collisions involving automobiles, buses, motorbikes, bicycles, lorries, or pedestrians.
In addition to these, factors that are believed to fuel the market growth of post-hemorrhagic anemia treatment include the growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders, such as hemophilia and Von Willebrand disease. In 2020, approximately 210,000 people in the world suffered from hemophilia, and about 84,000 were diagnosed with Von Willebrand disease. Along with these, rise in awareness levels regarding anemia, and escalating technological developments in the pharmaceutical sector, especially in developed and developing nations. Furthermore, surge in the percentage of population with a family history of anemia and blood diseases is projected to elevate the total number of cases of acute post-hemorrhagic anemia. This in turn is predicted to offer abundant growth opportunities to the market in the near future.
Global Post-Hemorrhagic Anemia Treatment Market: Growth Drivers and Challenges
Growth Drivers
-
Rising Cases of Blood Disorders– Hemophilia is a genetic blood condition that hinders the healthy clotting and coagulation of blood. Therefore, patients require frequent blood transfusion as a part of their treatment. Moreover, in the United States, around 18,400 people were diagnosed with hemophilia in the year 2021. Furthermore, around 10,000 people are suffering with other bleeding disorders.
-
Rising Incidents of Accidents– Accidents can cause severe injuries and lead to heavy blood loss; therefore, timely control of blood loss is an absolute necessity. According to the World Health Organization, every year around 1.3 million people die de to vehicle crash and in other road accidents. Moreover, over 50% of deaths on road is attributed to pedestrian, cyclists, and motorcyclists. In addition to this, road accidents are the primary cause of death for people between the age 5 to 29 years.
-
Rise in the Number of Surgical Procedures – Surgery involves massive blood loss that is likely to boost the demand for post-hemorrhagic anemia treatment. Around 40 to 50 million major procedures are performed annually in the USA, and about 20 million in Europe, for a startling total of nearly 310 million worldwide.
-
Rising Cases of Heart Patient– Heart patients are usually prescribed blood thinning medicines that increases the chances of post-hemorrhagic anemia. In the world, around 550 million people suffer from heart issues and circulation disorders. These problems are usually caused by unhealthy lifestyle & eating habits, and ageing population. Moreover, nearly 60 million people all over the world develops the heart disease, each year. This count is almost equal to entire population of the United Kingdom.
-
A Family History of Anemia – A person with anemia is already in deficiency of red blood cells and it can even worsen the situation in the case of post-hemorrhagic anemia. Therefore, post hemorrhagic anemia treatment can be used in aplastic anemia treatment, sickle-cell anemia treatment, and others. According to World Health Organization statistics, anemia affects 40% of pregnant women and 42% of children under the age of five worldwide.
Challenges
- Shortage of skilled workers – A patient suffering from post-hemorrhagic anemia can die if not handled under the immediate expert professionals. Therefore, lack of skilled workers is expected to hamper the market growth.
- A lack of some medical therapies' accessibility
- Lack of treatment awareness in certain under-developed regions
Global Post-Hemorrhagic Anemia Treatment Market Segmentation
The global post-hemorrhagic anemia treatment market is also segmented and analyzed for demand and supply by treatment into blood transfusion, surgery, iron supplements, extra oxygen, fluids, and others, out of which, the blood transfusion segment is anticipated to hold the largest share in the global post-hemorrhagic anemia treatment market. As a patient suffering from this type anemia quickly loses a large amount of blood, performing a blood transfusion becomes a necessity. Rising need for blood transfusion and rise in the collection of donated bloods is assessed to be a major factor to boost the growth of the market segment in the future. Globally, 118.5 million units of donated blood are collected year, but more would need to be collected to supply all the people who require transfusions. Furthermore, the patient suffering with sickle cell anemia, needs blood transfusion in every 4-6 weeks for a long period.
The global post-hemorrhagic anemia treatment market is segmented and analyzed for demand and supply by end user into hospitals, clinics, ambulatory surgical centers, and others. Out of all, the hospitals segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the high preference of patients to get treatment from a medical professional in a hospital facility. Apart from this, increase in number of patient admissions in hospitals is also forecasted to bolster the segment growth in the years to come.
Our in-depth analysis of the global post-hemorrhagic anemia treatment market includes the following segments:
|
By Treatment |
|
|
By End User |
|
Global Post-Hemorrhagic Anemia Treatment Market Regional Synopsis
The North America post-hemorrhagic anemia treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market in the region can be attributed majorly to the high number of hospital admissions, and the rising government focus to improve healthcare infrastructure in the region. Moreover, the market growth in North America is also credited to the rising number of people suffering from sickle cell anemia. In many severe cases, post-hemorrhagic anemia treatment is continued along the specific sickle cell disease drugs. Approximately 100,000 Americans are afflicted by sickle cell diseases. In addition to this, about 1 in every 365 Black or African-American babies is affected by SCD. Furthermore, the region’s market growth is attributed to high healthcare spending, and availability of well-established medical facilities in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion or USD 11,582 per person in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent that year. In addition, strong footprint of major market players is also predicted to propel the market growth in the region in the coming years.
The Asia-Pacific post-hemorrhagic anemia treatment market, amongst the market in all the other regions, is projected to hold the notable market share by the end of 2035. The growth of the market in the region can be majorly credited to rising cases of traffic accident and growing count of heart patient. As per the annual report from Ministry of Road Transport & Highways on road accidents in India 2021, there were 412,432 instances of road accidents in 2021, which resulted in 153,972 fatalities and 384,448 severe injuries. Furthermore, in Japan, the overall number of heart-related deaths reached about 206 thousand cases in 2020.
Top Featured Companies Dominating the Global Post-Hemorrhagic Anemia Treatment Market
- Rockwell Medical, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- Vifor Pharma Management Ltd.
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- AMAG Pharmaceuticals
- Akebia Therapeutics
